Alliance Pharma (LSE:APH) Total Liabilities : £236.8 Mil (As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Total Liabilities?

Alliance Pharma's Total Liabilities for the quarter that ended in Jun. 2023 was £236.8 Mil.

Alliance Pharma's quarterly Total Liabilities declined from Jun. 2022 (£251.64 Mil) to Dec. 2022 (£249.75 Mil) and declined from Dec. 2022 (£249.75 Mil) to Jun. 2023 (£236.76 Mil).

Alliance Pharma's annual Total Liabilities declined from Dec. 2020 (£227.90 Mil) to Dec. 2021 (£221.00 Mil) but then increased from Dec. 2021 (£221.00 Mil) to Dec. 2022 (£249.75 Mil).

Alliance Pharma Total Liabilities Historical Data

The historical data trend for Alliance Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Total Liabilities Chart

Alliance Pharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

151.41

133.46

227.90

221.00

249.75

Alliance Pharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Liabilities	Get a 7-Day Free Trial															233.79	221.00	251.64	249.75	236.76

Alliance Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alliance Pharma's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	47.022	+	(136.963	+	65.765
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	249.8

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	537.411	-	287.661
	=	249.8

Alliance Pharma's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	49.03	+	(123.708	+	64.023
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	236.8

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	513.72	-	276.959
	=	236.8

Alliance Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alliance Pharma (LSE:APH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

DVL:Germany

Address

Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB

Website

https://www.alliancepharmaceuticals.com

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).